Summary
XPH Chart
Is State Street SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?
The State Street SPDR S&P Pharmaceuticals ETF (XPH) made its debut on 06/19/2006, and is a smart beta exchange traded fund that provides broad exposure to the Health Care ETFs category of the market.
Should You Invest in the State Street SPDR S&P Pharmaceuticals ETF (XPH)?
Launched on June 19, 2006, the State Street SPDR S&P Pharmaceuticals ETF (XPH) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Pharma segment of the equity market.
Is State Street SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?
The State Street SPDR S&P Pharmaceuticals ETF (XPH) made its debut on 06/19/2006, and is a smart beta exchange traded fund that provides broad exposure to the Health Care ETFs category of the market.
SPDR S&P Pharmaceuticals ETF Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| TJD Thomas John Drogan PR Inc.IPAL SECURITIES Inc. | 6,151 | $300,727.71 | $416,668.74 | $115,941.03 | 38.55% |
 Kyle P. Smith NewEdge Wealth LLC | 4,033 | $173,393.2 | $273,235.75 | $99,842.55 | 57.58% |
 Kurt Van Dyken Lifeworks Advisors LLC | 4,503 | $243,567.27 | $304,290.22 | $60,722.95 | 24.93% |
| CAL CoreCap Advisors LLC CoreCap Advisors LLC | 41 | $1,768.33 | $2,749.46 | $981.13 | 55.48% |
| CWM Compass Wealth Management LLC Compass Wealth Management LLC | 24,153 | $1.34M | $1.64M | $302,935.92 | 22.6% |
SPDR S&P Pharmaceuticals ETF (XPH) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has SPDR S&P Pharmaceuticals ETF ever had a stock split?
SPDR S&P Pharmaceuticals ETF Profile
| ARCA Exchange | US Country |
Overview
The fund is designed to mirror the performance of the S&P Pharmaceuticals Select Industry Index. This Index is a subset of the S&P Total Market Index (S&P TMI) and specifically highlights the pharmaceuticals sector. To achieve its investment aim, the fund utilizes a sampling strategy. This means it doesn't necessarily invest in all the securities that the Index is composed of but selects a representative sample. By policy, the fund dedicates a substantial portion—if not all—of its assets towards investing in securities that make up the Index, committing at least 80% of its total assets to such investments.
Products and Services
- S&P Pharmaceuticals Select Industry Index Tracking:
The primary offering of the fund is its investment vehicle that aims to follow the performance of the S&P Pharmaceuticals Select Industry Index. This Index reflects the pharmaceuticals segment within the wider S&P Total Market Index. Through this product, investors gain exposure to a broad range of pharmaceutical companies without having to invest individually in each. It's a way to diversify one’s investment in the pharmaceutical sector efficiently and with reduced risk compared to picking single stocks.
- Sampling Strategy Investment Approach:
Unlike funds that practice full replication of their benchmark indices, this fund employs a sampling strategy. This method involves selecting a sample of securities that, in aggregate, are intended to approximate the full Index in terms of key risk factors, performance metrics, and other characteristics. This approach allows the fund to potentially reduce transaction costs and improve liquidity, making it an efficient way to achieve similar performance as the Index it tracks.
